Previous studies have indicated a significant upregulation of UCHL3 expression in several cancers, such as hepatocellular carcinoma, breast cancer, and colorectal cancer, correlating with poor prognosis and suggesting its potential as a therapeutic target [6–8]. The gene discussed is UCHL3; the disease is cancer.